OKYO Pharma Ltd (NASDAQ:OKYO) told investors that it is on track to release top-line results from its phase 2 clinical trial of OK-101 to treat dry eye.
OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, told investors it has filed an Investigational New Drug (IND) application with the US Food.
OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, has reported encouraging safety data for its ongoing phase II clinical trial of OK-101, a.
OKYO Pharma Ltd (NASDAQ:OKYO) has announced a public offering of its shares with the net proceeds to fund the clinical development of its product candidates.